Intrapartum oral azithromycin versus placebo alone or in combination with other antimicrobials on maternal infection in South East Asia

BACKGROUND: In low-resource facilities that routinely use intrapartum prophylactic antimicrobials, the use of multiple antimicrobials could be rationalised by a single oral dose of oral azithromycin. METHODS: The Azithromycin Prevention in Labor Use Study (A-PLUS), a randomized double-blind, placebo-controlled trial performed across eight sites in seven countries amongst women who planned to deliver vaginally. They were randomly assigned to receive study drug, a single intrapartum 2 gm oral dose of azithromycin or an identical appearing placebo. Data from four South-East Asia sites (Indian sites Nagpur and Belagavi, Pakistan, and Bangladesh) was analyzed to evaluate whether the use of non-study antimicrobials (alone or in-combination) given after randomization through one-day postpartum for any indication (prophylactic or treatment) modified the effect of study drugs on maternal outcomes (maternal infections, antibiotic usage 2-42days postpartum on ambulatory basis or re-hospitalization). The non-study antimicrobials given after randomization through 1-day postpartum was defined by four exposure sub-groups within azithromycin and placebo arm as, Use of: i) No non-study antibiotic; ii) Cephalosporin only; iii) Other non-study non-cephalosporin antibiotics; and iv) Cephalosporin and other non-study non-cephalosporin antibiotics. An intent to treat (ITT) analysis was adopted. Adjusted relative risks and 95% confidence intervals comparing azithromycin with placebo were estimated using Poisson regression models with robust variance estimators that included study site, maternal non-study antimicrobial use, and a treatment-by-non-study antimicrobial use interaction term. RESULTS: All maternal non-study antibiotic subgroups had balanced randomization between azithromycin and placebo. The risk of any maternal infections was reduced when only azithromycin was received versus placebo (RR = 0.75; 95% CI-0.57-0.98) and when group iv antimicrobials were used with azithromycin compared to only group iv antimicrobials (RR = 0.79; 95% CI-0.66-0.95). The use of antibiotics from day2-42 was similar in both arms (azithromycin or placebo) with or without use of other antimicrobials. CONCLUSIONS: This secondary analysis found no evidence that non-study antimicrobials use modified the effect of azithromycin on maternal outcomes. This study underscores the importance of considering an easily administrable intrapartum prophylaxis of oral monotherapy in low resource, high risk for infections sites to reduce antimicrobial resistance due to multiple antimicrobial use.

Authors

Institutions

Publication Details

Journal
PLoS ONE
Published
2026-11-18
DOI
https://doi.org/10.1371/journal.pone.0346359
Primary Topic
Neonatal and Maternal Infections
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Intrapartum oral azithromycin versus placebo alone or in combination with other antimicrobials on maternal infection in South East Asia

Marion W Koso-Thomas, Sarah Saleem, Janet Moore, Kunal Kurhe et al.
6 links
PLoS ONE
Neonatal and Maternal Infections
article

Intrapartum oral azithromycin versus placebo alone or in combination with other antimicrobials on maternal infection in South East Asia

Marion W Koso-Thomas, Sarah Saleem, Janet Moore, Kunal Kurhe, Shiyam Sunder Tikmani, Eleanor Nielsen, Denise C. Babineau, Waldemar A. Carlo, Jennifer Hemingway‐Foday, Sk Masum Billah, Patricia L. Hibberd, Richard J. Derman, Archana Patel, William A. Petri, Elizabeth M. McClure, Savita Bhargav, Poonam Shivkumar, Mrityunjay Chandrashekhar Metgud, Avinash J. Kavi, Rashidul Haque, Shivaprasad S. Goudar, Vaishali Khedikar, Robert L. Goldenberg, Saleem Jessani, Manjushri Waikar, Alan T N Tita
article en

Abstract

BACKGROUND: In low-resource facilities that routinely use intrapartum prophylactic antimicrobials, the use of multiple antimicrobials could be rationalised by a single oral dose of oral azithromycin. METHODS: The Azithromycin Prevention in Labor Use Study (A-PLUS), a randomized double-blind, placebo-controlled trial performed across eight sites in seven countries amongst women who planned to deliver vaginally. They were randomly assigned to receive study drug, a single intrapartum 2 gm oral dose of azithromycin or an identical appearing placebo. Data from four South-East Asia sites (Indian sites Nagpur and Belagavi, Pakistan, and Bangladesh) was analyzed to evaluate whether the use of non-study antimicrobials (alone or in-combination) given after randomization through one-day postpartum for any indication (prophylactic or treatment) modified the effect of study drugs on maternal outcomes (maternal infections, antibiotic usage 2-42days postpartum on ambulatory basis or re-hospitalization). The non-study antimicrobials given after randomization through 1-day postpartum was defined by four exposure sub-groups within azithromycin and placebo arm as, Use of: i) No non-study antibiotic; ii) Cephalosporin only; iii) Other non-study non-cephalosporin antibiotics; and iv) Cephalosporin and other non-study non-cephalosporin antibiotics. An intent to treat (ITT) analysis was adopted. Adjusted relative risks and 95% confidence intervals comparing azithromycin with placebo were estimated using Poisson regression models with robust variance estimators that included study site, maternal non-study antimicrobial use, and a treatment-by-non-study antimicrobial use interaction term. RESULTS: All maternal non-study antibiotic subgroups had balanced randomization between azithromycin and placebo. The risk of any maternal infections was reduced when only azithromycin was received versus placebo (RR = 0.75; 95% CI-0.57-0.98) and when group iv antimicrobials were used with azithromycin compared to only group iv antimicrobials (RR = 0.79; 95% CI-0.66-0.95). The use of antibiotics from day2-42 was similar in both arms (azithromycin or placebo) with or without use of other antimicrobials. CONCLUSIONS: This secondary analysis found no evidence that non-study antimicrobials use modified the effect of azithromycin on maternal outcomes. This study underscores the importance of considering an easily administrable intrapartum prophylaxis of oral monotherapy in low resource, high risk for infections sites to reduce antimicrobial resistance due to multiple antimicrobial use.

PLoS ONEVol. 21(11)
Boston University (US), Aga Khan University (PK), The University of Sydney (AU), Thomas Jefferson University (US), Government Medical College (IN), RTI International (US), International Centre for Diarrhoeal Disease Research (BD), University of Alabama at Birmingham (US), Lata Medical Research Foundation (IN), Jawaharlal Nehru Medical College (IN), KLE Academy of Higher Education and Research (IN), Eunice Kennedy Shriver National Institute of Child Health and Human Development (US), University of Virginia (US), Columbia University (US), Mahatma Gandhi Institute of Medical Sciences (IN)
Bill and Melinda Gates Foundation, RTI International, Thomas Jefferson University, National Institutes of Health, National Institute of Child Health and Human Development, Eunice Kennedy Shriver National Institute of Child Health and Human Development
Good health and well-being
Neonatal and Maternal Infections
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon